{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:56:52Z","timestamp":1790056612387,"version":"4.0.1"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2018-0116_s_001_w2aab3b7b5b1b6b1aab1c17b1Aa\">\n                    <jats:title id=\"d8956950e9762_w2aab3b7b5b1b6b1aab1c17b1aAa\">Background<\/jats:title>\n                    <jats:p>Peritoneal metastasis (PM) from gastric cancer often remains undiagnosed until it reaches an advanced stage. Despite curative management combining perioperative systemic chemotherapy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC), treated patients\u2019 5 year survival rate remains under 20\u2006% when patients are carefully selected. Palliative intravenous chemotherapy in patients with non-resectable cancer is frequently associated with poor long-term benefit and an estimated survival time below 1 year. Recently, two retrospectives studies reported that Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) improves patients\u2019 overall survival without impairing their quality of life (QoL). This promising result needs however to be studied on large randomized clinical trial to validate the effect of PIPAC on survival and QoL of patients with gastric PM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0116_s_002_w2aab3b7b5b1b6b1aab1c17b2Aa\">\n                    <jats:title id=\"d8956950e9771_w2aab3b7b5b1b6b1aab1c17b2aAa\">Methods<\/jats:title>\n                    <jats:p>PIPAC EstoK 01 is a prospective, open, randomized multicenter phase II clinical study with two arms that aims at evaluating the effects of PIPAC with doxorubicin and cisplatin on patients with PM of gastric cancer with peritoneal cancer index (PCI)&gt;8, treated with systemic chemotherapy between two PIPAC procedures. Patients were randomized at the end of explorative laparoscopy and after signing a written consent. Patients received in the first experimental arm a treatment associating PIPAC and systemic chemotherapy (1 PIPAC then 2 IV Chemo) and systemic chemotherapy only in the control arm. Primary endpoint was progression-free survival from the date of surgery to the date of death, or to the end of the 5 year follow-up. Secondary endpoint was 2 year overall survival, morbidity, QoL and secondary resectability rate. The number of patients randomized was calculated to be 94.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0116_s_003_w2aab3b7b5b1b6b1aab1c17b3Aa\">\n                    <jats:title id=\"d8956950e9780_w2aab3b7b5b1b6b1aab1c17b3aAa\">Trial registration<\/jats:title>\n                    <jats:p>Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2018-0116","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T18:49:24Z","timestamp":1531421364000},"source":"Crossref","is-referenced-by-count":65,"title":["PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study"],"prefix":"10.1515","volume":"3","author":[{"given":"Clarisse","family":"Eveno","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Lariboisi\u00e8re, Chirurgie Digestive et Canc\u00e9rologique , Paris , France"},{"name":"Sorbonne Paris Cit\u00e9 , Universit\u00e9 Paris7 Denis Diderot , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Jouvin","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Lariboisi\u00e8re, Chirurgie Digestive et Canc\u00e9rologique , Paris , France"},{"name":"Sorbonne Paris Cit\u00e9 , Universit\u00e9 Paris7 Denis Diderot , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Lariboisi\u00e8re, Chirurgie Digestive et Canc\u00e9rologique , Paris , France"},{"name":"Sorbonne Paris Cit\u00e9 , Universit\u00e9 Paris7 Denis Diderot , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"2025120909215699927_j_pp-2018-0116_ref_001_w2aab3b7b5b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andr\u00e9 T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (f\u00e9d\u00e9ration francophone de canc\u00e9rologie digestive, f\u00e9d\u00e9ration nationale des centres de lutte contre le cancer, and groupe coop\u00e9rateur multidisciplinaire en oncologie) study. J Clin Oncol 2014;32:3520\u20136.25287828","DOI":"10.1200\/JCO.2013.54.1011"},{"key":"2025120909215699927_j_pp-2018-0116_ref_002_w2aab3b7b5b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687\u201397.10.1016\/S0140-6736(10)61121-X","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2025120909215699927_j_pp-2018-0116_ref_003_w2aab3b7b5b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374.10.1007\/978-1-4613-1247-5_238849962","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909215699927_j_pp-2018-0116_ref_004_w2aab3b7b5b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, et al. BIG RENAPE Group. patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility?. Ann Surg Oncol 2016;23:1971\u20139.10.1245\/s10434-015-5081-3","DOI":"10.1245\/s10434-015-5081-3"},{"key":"2025120909215699927_j_pp-2018-0116_ref_005_w2aab3b7b5b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139.10.1245\/s10434-013-3213-124006094","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909215699927_j_pp-2018-0116_ref_006_w2aab3b7b5b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Nadiradze G J, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. Gastrointest Surg 2016;20:367\u201373.10.1007\/s11605-015-2995-9","DOI":"10.1007\/s11605-015-2995-9"},{"key":"2025120909215699927_j_pp-2018-0116_ref_007_w2aab3b7b5b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Khomyakov V, Ryabov A, Ivanov A, Bolotina L, Utkina A, Volchenko N, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura and Peritoneum 2016;1:159\u201366.","DOI":"10.1515\/pp-2016-0017"},{"key":"2025120909215699927_j_pp-2018-0116_ref_008_w2aab3b7b5b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol 2017;43:2178\u201383.10.1016\/j.ejso.2017.09.01028964609","DOI":"10.1016\/j.ejso.2017.09.010"},{"key":"2025120909215699927_j_pp-2018-0116_ref_009_w2aab3b7b5b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Sola\u00df W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012;26:1849\u201355.10.1007\/s00464-012-2148-022580869","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909215699927_j_pp-2018-0116_ref_010_w2aab3b7b5b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Eveno C, Haidara A, Ibrahim A, Pimpie C, Mirshahi M, Pocard M. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura & Peritoneum 2017;2:103\u20139.","DOI":"10.1515\/pp-2017-0015"},{"key":"2025120909215699927_j_pp-2018-0116_ref_011_w2aab3b7b5b1b6b1ab1b5c11Aa","unstructured":"Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 2018 May 6 pii: S0090-8258(18)30851\u20135."},{"key":"2025120909215699927_j_pp-2018-0116_ref_012_w2aab3b7b5b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36\u201346.1817217310.1056\/NEJMoa073149","DOI":"10.1056\/NEJMoa073149"},{"key":"2025120909215699927_j_pp-2018-0116_ref_013_w2aab3b7b5b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2008;26:1435\u201342.1834939310.1200\/JCO.2007.13.9378","DOI":"10.1200\/JCO.2007.13.9378"},{"key":"2025120909215699927_j_pp-2018-0116_ref_014_w2aab3b7b5b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006;24:4991\u20137.10.1200\/JCO.2006.06.8429","DOI":"10.1200\/JCO.2006.06.8429"},{"key":"2025120909215699927_j_pp-2018-0116_ref_015_w2aab3b7b5b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 2017;3:1237\u201344.10.1001\/jamaoncol.2017.051528448662","DOI":"10.1001\/jamaoncol.2017.0515"},{"key":"2025120909215699927_j_pp-2018-0116_ref_016_w2aab3b7b5b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, et al. III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). Dig Liver Dis 2018;50:408\u201310.2940977810.1016\/j.dld.2018.01.119","DOI":"10.1016\/j.dld.2018.01.119"},{"key":"2025120909215699927_j_pp-2018-0116_ref_017_w2aab3b7b5b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura and Peritoneum 2016;1:99\u2013107.","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909215699927_j_pp-2018-0116_ref_018_w2aab3b7b5b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol 2013;20:3504\u201311.2376541710.1245\/s10434-013-3039-x","DOI":"10.1245\/s10434-013-3039-x"},{"key":"2025120909215699927_j_pp-2018-0116_ref_019_w2aab3b7b5b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370\u20137.10.1245\/s10434-010-1039-720336386","DOI":"10.1245\/s10434-010-1039-7"},{"key":"2025120909215699927_j_pp-2018-0116_ref_020_w2aab3b7b5b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"Fava BEC, Da Costa WL, Jr, Medeiros MLL, Sonagli M, De Castro Ribeiro HS, Diniz AL, et al. Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center. World J Surg Oncol 2018;16:62.10.1186\/s12957-018-1363-0","DOI":"10.1186\/s12957-018-1363-0"},{"key":"2025120909215699927_j_pp-2018-0116_ref_021_w2aab3b7b5b1b6b1ab1b5c21Aa","doi-asserted-by":"crossref","unstructured":"Girshally R, Demtr\u00f6der C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2016;14:253.2767834410.1186\/s12957-016-1008-0","DOI":"10.1186\/s12957-016-1008-0"},{"key":"2025120909215699927_j_pp-2018-0116_ref_022_w2aab3b7b5b1b6b1ab1b5c22Aa","doi-asserted-by":"crossref","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 2016;20:367\u201373.10.1007\/s11605-015-2995-926511950","DOI":"10.1007\/s11605-015-2995-9"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/3\/2\/article-20180116.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0116\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:53:27Z","timestamp":1765277607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0116\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6,12]]},"published-print":{"date-parts":[[2018,6,26]]}},"alternative-id":["10.1515\/pp-2018-0116"],"URL":"https:\/\/doi.org\/10.1515\/pp-2018-0116","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"article-number":"20180116"}}